Balyasny Asset Management
PRVL

Balyasny Asset Management’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Balyasny Asset Management’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-277,374
Closed -$6.4M – 2252
2020
Q4 		$6.4M Buy
+277,374
New +$3.52M 0.04% 573

Balyasny Asset Management's PRVL Position: Q1 2021 in Review

Balyasny Asset Management sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 277,374 shares — an estimated $6.4M sold.

Balyasny Asset Management first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $6.4M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Balyasny Asset Management reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Balyasny Asset Management sold 277,374 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $6.4M.
  • Balyasny Asset Management first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Balyasny Asset Management's Prevail Therapeutics Inc. Common Stock position peaked at $6.4M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Balyasny Asset Management's 13F filing for Q1 2021, filed 17 May 2021.